MARKET

SLRX

SLRX

Salarius Pharmaceuticals Inc
NASDAQ
1.710
-0.100
-5.52%
Closed 19:11 02/12 EST
OPEN
1.810
PREV CLOSE
1.810
HIGH
1.810
LOW
1.710
VOLUME
61.35K
TURNOVER
0
52 WEEK HIGH
7.20
52 WEEK LOW
1.220
MARKET CAP
2.71M
P/E (TTM)
-0.2088
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SLRX last week (0203-0207)?
Weekly Report · 2d ago
Salarius announces patient enrollment to resume for trial on seclidemstat
TipRanks · 02/03 13:16
SALARIUS PHARMACEUTICALS ANNOUNCES PATIENT ENROLLMENT TO RESUME IN INVESTIGATOR-INITIATED PHASE 1/2 CLINICAL TRIAL USING SECLIDEMSTAT WITH AZACITIDINE TO TREAT HEMATOLOGIC CANCERS
Reuters · 02/03 13:00
Weekly Report: what happened at SLRX last week (0127-0131)?
Weekly Report · 02/03 11:19
Weekly Report: what happened at SLRX last week (0120-0124)?
Weekly Report · 01/27 11:23
Salarius Pharmaceuticals files to sell common stock, warrants, no amount given
TipRanks · 01/21 13:11
Weekly Report: what happened at SLRX last week (0113-0117)?
Weekly Report · 01/20 11:14
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Benzinga · 01/17 19:58
More
About SLRX
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening and further optimization with structure-activity relationship studies.

Webull offers Salarius Pharmaceuticals Inc stock information, including NASDAQ: SLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLRX stock methods without spending real money on the virtual paper trading platform.